Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: Management of stage IV disease

J Am Acad Dermatol. 2013 Jan;68(1):13.e1-13; quiz 26-8. doi: 10.1016/j.jaad.2012.09.041.

Abstract

Part II of this continuing medical education article will discuss the treatment options for stage IV melanoma, including novel therapies, such as ipilimumab and vemurafenib; established therapies, including high-dose interleukin-2, conventional chemotherapy, and biochemotherapy; and additional therapies currently under investigation in the form of clinical trials. The approach to patients with brain metastases will be discussed, as will recommendations for distress screening and defining aspects of palliative care.

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Brain Neoplasms / secondary*
  • Brain Neoplasms / therapy*
  • Dacarbazine / therapeutic use
  • Humans
  • Immunologic Factors / therapeutic use
  • Indoles / therapeutic use
  • Interleukin-2 / therapeutic use
  • Ipilimumab
  • Melanoma / secondary*
  • Melanoma / therapy*
  • Neoplasm Staging
  • Palliative Care*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Proto-Oncogene Proteins c-kit / genetics
  • Radiosurgery
  • Skin Neoplasms / pathology*
  • Skin Neoplasms / therapy*
  • Sulfonamides / therapeutic use
  • Vemurafenib
  • raf Kinases / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Immunologic Factors
  • Indoles
  • Interleukin-2
  • Ipilimumab
  • Sulfonamides
  • Vemurafenib
  • Dacarbazine
  • Protein-Tyrosine Kinases
  • Proto-Oncogene Proteins c-kit
  • raf Kinases